Phase 2 B-cell Non Hodgkin Lymphoma Clinical Trials
12 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–12 of 12 trials
Recruiting
Phase 1Phase 2
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Mantle Cell LymphomaSmall Lymphocytic LymphomaB-cell Non Hodgkin Lymphoma+2 more
AstraZeneca408 enrolled64 locationsNCT06564038
Recruiting
Phase 1Phase 2
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
B-cell Non Hodgkin Lymphoma
AstraZeneca91 enrolled22 locationsNCT07123454
Recruiting
Phase 2
Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma
Relapsed B-Cell Non Hodgkin Lymphoma
ImmunityBio, Inc.20 enrolled2 locationsNCT07125872
Recruiting
Phase 2
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
B-cell Non Hodgkin LymphomaBurkitt LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements+6 more
University of Washington18 enrolled1 locationNCT07097363
Recruiting
Phase 1Phase 2
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
B-cell Non Hodgkin LymphomaB-cell Acute Lymphoblastic Leukemia
University of Colorado, Denver45 enrolled1 locationNCT04544592
Recruiting
Phase 1Phase 2
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
Chronic Lymphocytic LeukemiaB-cell Non Hodgkin Lymphoma
Medical University of South Carolina27 enrolled1 locationNCT05702853
Recruiting
Phase 2
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
B-cell Non Hodgkin LymphomaFollicular Lymphoma ( FL)Large B-Cell Lymphoma (LBCL)
AstraZeneca240 enrolled94 locationsNCT06526793
Recruiting
Phase 2Phase 3
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
B-cell Non Hodgkin Lymphoma
University of Birmingham210 enrolled11 locationsNCT05991388
Recruiting
Phase 2
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
B-cell Non Hodgkin Lymphoma
Northwestern University32 enrolled2 locationsNCT06242834
Recruiting
Phase 2
CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors
B-cell Non Hodgkin Lymphoma
Ruijin Hospital16 enrolled1 locationNCT06365671
Recruiting
Phase 2
Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
Multiple MyelomaB-cell Non Hodgkin Lymphoma
City of Hope Medical Center164 enrolled1 locationNCT06052826
Recruiting
Phase 1Phase 2
Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
B-cell Non Hodgkin Lymphoma
AbClon82 enrolled1 locationNCT05338931